Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
3.
J Pediatr Endocrinol Metab ; 21(5): 455-60, 2008 May.
Artigo em Inglês | MEDLINE | ID: mdl-18655527

RESUMO

The incidence of 21-hydroxylase deficiency (CYP21 D) congenital adrenal hyperplasia (CAH) in Brazil is purportedly one of the highest in the world (1:7,533). However, this information is not based on official data. The aim of this study was to determine the incidence of CYP21 D CAH in the state of Goiás, Brazil, based on the 2005 results of government-funded mandatory screening. Of the live births during this period, 92.95% were screened by heel-prick capillary 17alpha-hydroxyprogesterone (17-OHP). Of these, 82,343 were normal, 28 were at high risk for CAH and 232 at low risk for CAH. Eight cases, all from the high risk group, were confirmed. Eight asymptomatic children at 6-18 months of age still have high 17-OHP levels and await diagnostic definition. Based on the number of confirmed CYP21 D CAH cases among the 82,603 screened, the estimated annual incidence of the disease was 1:10,325, lower than the previously reported rate in Brazil.


Assuntos
Hiperplasia Suprarrenal Congênita/epidemiologia , Triagem Neonatal/métodos , 17-alfa-Hidroxiprogesterona/sangue , Hiperplasia Suprarrenal Congênita/sangue , Hiperplasia Suprarrenal Congênita/diagnóstico , Brasil/epidemiologia , Feminino , Humanos , Incidência , Lactente , Recém-Nascido , Masculino , Reprodutibilidade dos Testes , Esteroide 21-Hidroxilase/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...